|Calculated MW||65 kDa, homodimer, glycosylated|
|Other Names||SYM1, SYNS1, NOG.|
|Source||Human 293 cell expressed|
|Assay&Purity||SDS-PAGE; > 95%|
|Results||20 to 100 ng/ml|
|Application Notes||Reconstitute in sterile PBS containing 0.1% endotoxin-free recombinant human serum albumin.|
|Storage||-80°C; Lyophilized in PBS.|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Noggin belongs to a group of diffusible proteins which bind to ligands of the TGF-β family and regulate their activity by inhibiting their access to signaling receptors. Noggin was originally identified as a BMP-4 antagonist whose action is critical for proper formation of the head and other dorsal structures. Consequently, Noggin has been shown to modulate the activities of other BMPs including BMP-2,-7,-13, and -14. Targeted deletion of Noggin in mice results in prenatal death and recessive phenotype displaying a severely malformed skeletal system. Conversely, transgenic mice over-expressing Noggin in mature osteoblasts display impaired osteoblastic differentiation, reduced bone formation, and severe osteoporosis.
Valenzuela D.M.,et al.J. Neurosci. 15:6077-6084(1995).
Groppe J.,et al.Nature 420:636-642(2002).
Gong Y.,et al.Nat. Genet. 21:302-304(1999).
Takahashi T.,et al.Clin. Genet. 60:447-451(2001).
Dixon M.E.,et al.Genet. Med. 3:349-353(2001).
If you have any additional inquiries please email technical services at firstname.lastname@example.org.